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Introduction {#sec001}
============

Hearing loss (HL) is one of the most common sensorineural disorders, affecting 1--2 neonates in every 1000 and the prevalence increases with age \[[@pone.0165650.ref001]\]. In fact, 50% to 60% of childhood HL can be attributed to genetic defects\[[@pone.0165650.ref001]\]. With at least 100 genes identified to date (<http://heretidaryhearingloss.org/>, updated in Sep. 2016), non-syndromic HL (NSHL, with no symptoms in other organs) is an extraordinarily heterogeneous trait. Autosomal recessive (AR) NSHL is typically pre-lingual and is present in \~80% of HL cases. *GJB2* is (OMIM\*121011) the most common gene involved in ARNSHL. In some populations, pathogenic *GJB2* variants account for up to 50% of all ARNSHL cases \[[@pone.0165650.ref002]\]. *SLC26A4* (OMIM\*605646), the second most frequent gene involved in ARNSHL and is present in 4--10% of NSHL cases among different populations \[[@pone.0165650.ref003]--[@pone.0165650.ref005]\]. A defect in the mitochondrial gene, *MT-RNR1*, is associated with extreme sensitivity to aminoglycoside ototoxicity and accounts for maternally inherited NSHL \[[@pone.0165650.ref006], [@pone.0165650.ref007]\]. The traditional method for diagnosis of NSHL relied on Sanger sequencing. Although direct sequencing is the gold standard approach for genetic testing, it is expensive, time consuming and has low throughput. An SNPscan technique has been developed, using a patented SNP genotyping technology based on a double ligation reaction and multiplex fluorescence PCR, which is able to perform multiplex (48--192) genotyping for up to 192 kinds of SNPs\[[@pone.0165650.ref008]\]. This technique is uniquely suited to genetic screening for NSHL due to the extremely strong genetic heterogeneity of NSHL. In the current study, the majority of pathogenic variants of *GJB2*, *SLC26A4* and *MT-RNR1* were obtained and a primary genetic test for NSHL was designed using an SNPscan genotyping technique with the ability to simultaneously detect 115 different variants in *GJB2* (n = 36), *SLC26A4* (n = 77), and *MT-RNR1* (n = 2), the common genes related to HL.

Materials and Methods {#sec002}
=====================

Subjects and Auditory Evaluation {#sec003}
--------------------------------

A total of 695 affected subjects were recruited in 2014. Patients from the Department of Otolaryngology (n = 132), 3^rd^ Hospital of Peking University (n = 132) and from 12 different rehabilitation centers for the deaf around the area of Beijing, China (n = 563) were included. This study was approved by the Ethics Committee of 3^rd^ Hospital of Peking University (Approval number 20141212). Written informed consent was obtained from adult participants and from guardians on behalf of minors/children prior to their participation in the study. A comprehensive medical history was obtained from each subject via a questionnaire regarding onset age, evolution, degree and symmetry of hearing loss, hearing aids, cochlear implants, presence of tinnitus, pressure in the ears, vertigo, history of noise exposure and other relevant clinical manifestations. Each participant received a physical examination to exclude any additional distinguishing physical findings. A comprehensive auditory evaluation, including otoscopy, pure-tone audiometry (PTA, at frequencies from 500 to 4000Hz) and immittance testing was performed. The severity of HL was defined according to PTA as mild (26-40dBHL), moderate (41--70dBHL), severe (71-90dBHL) or profound (\> 90dBHL). Middle ear pressure, ear canal volume and tympanic membrane mobility was evaluated according to immittance testing.

Screening of *GJB2*, *SLC26A4* and *MT-RNR1* {#sec004}
--------------------------------------------

Peripheral blood samples (2 ml) were drawn from all subjects for DNA extraction and genetic analysis. Genomic DNA was isolated from whole blood using a DNA extraction kit (Axygen Scientific Inc., Union City, CA, USA). A total of 115 variants of *GJB2* (NM_004004, n = 36), *SLC26A4* (NM_000441, n = 77) and *MT-RNR1*(NR_137294, n = 2) were included. Of these, 97 pathogenic variants (*GJB2* = 18, *SLC26A4* = 77, *MT-RNR1* = 2) were pathogenic and 18 *GJB2* variants were unclassified. All the 97 pathogenic variants of *GJB2*, *SLC26A4* and *MT-RNR1* genes included in this primary screening system were taken from deafness variant database (<http://deafnessvariationdatabase.org>) where clear indication of the pathogenicity associated with HL were given. Screening of these pathogenic variants in common HL genes was carried out to establish molecular diagnosis for HL cases. Genetic analysis was performed using a custom-built 48-Plex SNPscanTM Kit (Genesky Biotechnologies Inc., Shanghai, China).

Results {#sec005}
=======

Based on the questionnaires, HL in 568 subjects was pre-lingual, HL in 47 subjects was post-lingual, and the age of HL onset in 80 subjects was uncertain. According to audiograms, the severity of sensorineural hearing loss was mild (n = 1), moderate (n = 15), severe (n = 69) and profound (n = 610). Thirteen subjects had a history of noise exposure and 60 subjects had a history of using aminoglycoside antibiotics (dosage uncertain), such as gentamicin and/or streptomycin. The mothers of 65 subjects suffered from possible viral infections, such as colds or urticaria, during the first 3 months of pregnancy. Comprehensive family medical histories and clinical examinations found no additional clinical abnormalities, such as cardiovascular disease, kidney disease, visual problems or neurological disorders, in any subject ([Table 1](#pone.0165650.t001){ref-type="table"}).

10.1371/journal.pone.0165650.t001

###### Clinical Information of 695 Chinese HL Subjects.

![](pone.0165650.t001){#pone.0165650.t001g}

  Onset age        Hearing loss   Environmental factors                        
  ----------- ---- -------------- ----------------------- ---- ---- ----- ---- ----
  568         47   80             1                       15   69   610   13   60

*GJB2*  {#sec006}
-------

### Pathogenic variants {#sec007}

Genetic analysis revealed that 17 subjects carried only one *GJB2* mutant allele and 129 (18.6%, 129/695) subjects carried bi-allelic pathogenic variants in *GJB2*, including 57 homozygotes and 72 compound heterozygotes ([Fig 1](#pone.0165650.g001){ref-type="fig"}). Therefore, the allele frequency of pathogenic variants in *GJB2* gene was 19.8% (275/1390). The allele frequency of c.235delC, the most prevalent pathogenic variant of *GJB2*, was 13.0% (181/1390), followed by c.299_300 del AT, c.257C \> G, c.34_35insG and c.511_512insAACG with allele frequencies of 4.5% (63/1390), 0.58% (8/1390), 0.43% (6/1390) and 0.43% (6/1390), respectively. These 5 pathogenic variants account for 96.0% (264/275) of all *GJB2* mutant alleles. In addition, c.235delC was a compound heterozygote, with 9 different pathogenic variants, in 73 patients and was present as a mono-allelic variant in 2 patients who carried bi-allelic pathogenic variants of *SLC26A4*. Overall, 11 pathogenic variants of *GJB2* ([Fig 2](#pone.0165650.g002){ref-type="fig"}) constituted 14 different genotypes ([Table 2](#pone.0165650.t002){ref-type="table"}).

![Molecular etiology of 695 Chinese patients with NSHL.\
The percentages of biallelic *GJB2*, *SLC26A4* and homoplasmic *MT-RNR1* pathogenic variants were 18.6%, 20.1% and 0.72%, respectively. Screening of 97 different pathogenic variants in 3 genes revealed that 129 (18.6%, 129/695) cases carried biallelic *GJB2* variants and 140 patients (20.1%,140/695) carried biallelic *SLC26A4* variants. Homoplasmic *MT-RNR1* m.1555A \> G occurred in 5 cases (0.72%,5/695), however, *MT-RNR1* variants are not necessarily causative for HL.](pone.0165650.g001){#pone.0165650.g001}

![Location of pathogenic variants of *GJB2* and *SLC26A4* in the 695 subjects with NSHL.\
(a)Overall, 11 different *GJB2* pathogenic variants were identified in 695 subjects, out of which, one subject carried a heterozygous c.IVS1+1G \> A mutant allele. The number of the mutant alleles of the other 10 different pathogenic variants, c.9G\>A, c.34_35insG, c.139G\>T, c.176_191del16, c.230G\>A, c.235delC, c.257C\>G, c.299_300delAT, c.427C\>T and c.511_512insAACG are shown here. (b) In addition, 41 *SLC26A4* pathogenic variants were identified in 695 subjects, the number of the mutant alleles of the most frequent 9 variants, c.414delT, c.919-2A\>G, c.1174A\>T, c.1226G\>A, c.1229C\>T, c.1707+5G\>A, c.1975G\>C, c.2027T\>A and c.2168A\>G are shown here.](pone.0165650.g002){#pone.0165650.g002}

10.1371/journal.pone.0165650.t002

###### Chinese Patients with Bi-allelic Pathogenic variants in *GJB2*.

![](pone.0165650.t002){#pone.0165650.t002g}

  Genotypes                        Number (%) of patients   Inheritance mode                           Clinical information   
  -------------------------------- ------------------------ ------------------------------------------ ---------------------- ------------------------
  **Homozygous**                                                                                                              
  c.235delC/ c.235delC             52 (7.48%)               AR [\*](#t002fn001){ref-type="table-fn"}   Severe, profound       Did not pass NBHS\~ 13
  c.299_300delAT/ c.299_300delAT   5 (0.72%)                AR                                         Profound               3 months\~3.5
  **Compound heterozygous**                                                                                                   
  c.235delC/c.299_300delAT         40 (5.76%)               AR                                         Severe, profound       6 months\~3.5
  c.235delC/c.34_35insG            6 (0.86%)                AR                                         Severe, profound       1\~5
  c.235delC/c.511_512insAACG       6 (0.86%)                AR                                         Severe, profound       9 months\~5
  c.235delC/c.257C\>G              4 (0.58%)                AR                                         Severe, profound       6months\~3
  c.235delC/c.427C\>T              4 (0.58%)                AR                                         Severe, profound       11 months\~4
  c.235delC/c.176_191del16         3 (0.43%)                AR                                         Profound               1\~2.5
  c.299_300delAT/c.257C\>G         3 (0.43%)                AR                                         Severe, profound       Did not pass NBHS \~2
  c.235delC/c.9G\>A                2 (0.29%)                AR                                         Severe, profound       1\~3
  c.176_191del16/c.230G\>A         1 (0.14%)                AR                                         Profound               1.5
  c.176_191del16/c.139G\>T         1 (0.14%)                AR                                         Profound               4
  c.235delC/c.IVS1+1G\>A           1 (0.14%)                AR                                         Severe                 1
  c.299_300delAT/c.427C\>T         1 (0.14%)                AR                                         Severe                 6 months
  Total                            129 (18.6%)                                                                                

\*AR: Autosomal recessive

### Unclassified variants {#sec008}

Genetic analysis of 18 unclassified *GJB2* variants revealed that 7 variants in 50 cases. Specifically, 3 cases carried bi-allelic variants (one c. 95G \> A homozygote and 2 c.109G \> A homozygotes) and 47 cases carried 1 *GJB2* variant. The allele frequency of c.109G \> A was 3.2% (44/1390) and c.95G \> A, c.283G \> A, and c.571T \> C shared the same allele frequency of 0.14% (2/1390). Moreover, c.23C \> T, c.408C \> A and c.416G \> A occurred in one case each as a heterozygous variant, sharing an allele frequency of 0.07% (1/1390) (Tables [3](#pone.0165650.t003){ref-type="table"} and [4](#pone.0165650.t004){ref-type="table"}).

10.1371/journal.pone.0165650.t003

###### Unclassified *GJB2* variants in Patients with NSHL.

![](pone.0165650.t003){#pone.0165650.t003g}

  Variants               Number of patients   Clinical information   
  ---------------------- -------------------- ---------------------- -----------------------------------------------------------
  **Homozygous**                                                     
  c.95G\>A/ c.95G\>A     1                    Profound               Unclear
  c.109G\>A /c.109G\>A   2                    Mild                   3
  Profound               6 months                                    
  **Heterozygous**                                                   
  c.23C\>T               1                    Severe                 1
  c.109G\>A              40                   Moderate-profound      Did not pass NBHS[\*](#t003fn001){ref-type="table-fn"}\~4
  c.283G\>A              2                    Severe-profound        6 months\~5
  c.408C\>A              1                    Profound               5
  c.416G\>A              1                    Severe                 6
  c.571T\>C              2                    Severe, profound       6 months \~2
  Total                  50                                          

\*NBHS: Newborn hearing screening

10.1371/journal.pone.0165650.t004

###### The allele frequency of Unclassified *GJB2* variants in Patients with NSHL.

![](pone.0165650.t004){#pone.0165650.t004g}

  Variants    Number (%)of mutant alleles   Allele frequency in Database           
  ----------- ----------------------------- ------------------------------ ------- ---------------------------
  c.23C\>T    1(0.07%)                      0%                             0%      \-
  c.95G\>A    2(0.14%)                      0%                             \-      \-
  c.109G\>A   44(3.2%)                      7.2%                           3.9%    GO-ESP 0.13%; GMAF 1.5%
  c.283G\>A   2(0.14%)                      0%                             0%      GMAF 0.02%
  c.408C\>A   1(0.07%)                      0%                             \-      \-
  c.416G\>A   1(0.07%)                      0.01%                          0.49%   GO-ESP 0.054%; GMAF 0.04%
  c.571T\>C   2(0.14%)                      0.2%                           0.49%   GMAF 0.02%

-: no record

*SLC26A4*  {#sec009}
----------

A total of 164 patients (23.6%, 164/695) had molecular defects in the *SLC26A4* gene and 140 patients (20.1%, 140/695) carried bi-allelic pathogenic variants in *SLC26A4* ([Fig 2](#pone.0165650.g002){ref-type="fig"}), including 54 homozygotes and 86 compound heterozygotes. Twenty-four cases carried a heterozygous *SLC26A4* mutant allele and 3 of these also carried bi-allelic pathogenic variants of *GJB2*. Thus, the mutant allele frequency of *SLC26A4* was 21.9% (304 /1390). Genetic analysis of *SLC26A4* revealed 52 different genotypes ([Table 5](#pone.0165650.t005){ref-type="table"}) comprised by 41 *SLC26A4* variants ([Table 6](#pone.0165650.t006){ref-type="table"}). The 5 most prevalent pathogenic variants in *SLC26A4* were c.919-2A \> G (12.2%, 169/1390), c.2168A \> G (2.5%, 35/1390), c.1975G \> C (1.0%,14/1390), c.1174A \> T (0.65%,9/1390) and c.1707+5G \> A(0.5%, 7/1390), and accounted for 77.0% (234/304) of all mutant *SLC26A4* alleles([Fig 2](#pone.0165650.g002){ref-type="fig"}). The most prevalent pathogenic variant, c.919-2A \> G, accounting for 55.6% (169/304) of all *SLC26A4* mutant alleles, was in compound heterozygosity with 24 different *SLC26A4* variants in 60 cases.

10.1371/journal.pone.0165650.t005

###### Chinese Patients with Bi-allelic Pathogenic variants in *SLC26A4*.

![](pone.0165650.t005){#pone.0165650.t005g}

  Genotypes                     Number (%) of patients   Inheritance mode                           Clinical information         
  ----------------------------- ------------------------ ------------------------------------------ ---------------------------- -----------------------
  **Homozygous**                                                                                                                 
  c.919-2A\>G/c.919-2A\>G       50 (7. 19%)              AR [\*](#t005fn001){ref-type="table-fn"}   Moderate, severe, profound   Did not pass NBHS\~ 8
  c.414delT/c.414delT           2 (0. 29%)               AR                                         Profound                     5 months, 1
  c.1707+5G\>A/c.1707+5G\>A     1 (0. 14%)               AR                                         Profound                     2
  c.2168A\>G/c.2168A\>G         1 (0. 14%)               AR                                         Profound                     2
  **Compound heterozygous**                                                                                                      
  c.919-2A\>G/c.2168A\>G        17 (2. 44%)              AR                                         Moderate, severe, profound   6 months \~11
  c.919-2A\>G/c.1975G\>C        9 (1. 29%)               AR                                         Severe, profound             2 \~3. 5
  c.919-2A\>G/c.1174A\>T        3 (0. 43%)               AR                                         Severe, profound             2\~3
  c.919-2A\>G/c.1226G\>A        3 (0. 43%)               AR                                         Profound                     2\~3
  c.919-2A\>G/c.1707+5G\>A      3 (0. 43%)               AR                                         Severe, profound             8months\~2
  c.919-2A\>G/c.279T\>A         2 (0. 29%)               AR                                         Profound                     2, 4
  c.919-2A\>G/c.754T\>C         2 (0. 29%)               AR                                         Profound                     2, 7
  c.919-2A\>G/c.916_917insG     2 (0. 29%)               AR                                         Profound                     1\. 5, 3
  c.919-2A\>G/c.1225C\>T        2 (0. 29%)               AR                                         Severe, profound             1, 2
  c.919-2A\>G/c.1229C\>T        2 (0. 29%)               AR                                         Profound                     2, 4
  c.2168A\>G/c.1174A\>T         2 (0. 29%)               AR                                         Severe, profound             2, 3. 5
  c.919-2A\>G/c.1343C\>T        2 (0. 29%)               AR                                         Severe, profound             2\~3
  c.2168A\>G/c.1927G\>T         2 (0. 29%)               AR                                         Moderate, severe             1, 1
  c.2168A\>G/c.227C\>T          1 (0. 14%)               AR                                         Severe                       1
  c.235C\>T/c.1594A\>C          1 (0. 14%)               AR                                         Profound                     2
  c.249G\>A/c.1707+5G\>A        1 (0. 14%)               AR                                         Severe                       2\. 5
  c.269C\>T/c.1229C\>T          1 (0. 14%)               AR                                         Severe                       4
  c.281C\>T/c.919-2A\>G         1 (0. 14%)               AR                                         Severe                       2
  c.281C\>T/c.1174A\>T          1 (0. 14%)               AR                                         Profound                     2
  c.414delT/c.919-2A\>G         1 (0. 14%)               AR                                         Profound                     1
  c.439A\>G/c.2027T\>A          1 (0. 14%)               AR                                         Profound                     3
  c.563T\>C/c.919-2A\>G         1 (0. 14%)               AR                                         Profound                     2
  c.563T\>C/c.2168A\>G          1 (0. 14%)               AR                                         Profound                     12
  c.589G\>A/c.2168A\>G          1 (0. 14%)               AR                                         Profound                     1\. 5
  c.754T\>C/c.1226G\>A          1 (0. 14%)               AR                                         Profound                     6
  c.916_917insG/c.1975G\>C      1 (0. 14%)               AR                                         Severe                       1
  c.919-2A\>G/c.946G\>T         1 (0. 14%)               AR                                         Profound                     2
  c.919-2A\>G/c.1079C\>T        1 (0. 14%)               AR                                         Profound                     2
  c.919-2A\>G/c.1173C\>A        1 (0. 14%)               AR                                         Severe                       3
  c.919-2A\>G/c.1340delA        1 (0. 14%)               AR                                         Profound                     4
  c.919-2A\>G/c.1343C\>A        1(0. 14%)                AR                                         Severe                       2
  c.919-2A\>G/c.1371C\>A        1 (0. 14%)               AR                                         Profound                     1
  c.919-2A\>G/c.1489G\>A        1 (0. 14%)               AR                                         Profound                     3
  c.919-2A\>G/c.1547_1548InsC   1 (0. 14%)               AR                                         Severe                       1
  c.919-2A\>G/c.1586T\>G        1 (0. 14%)               AR                                         Moderate                     10
  c.919-2A\>G/c.1673A\>T        1 (0. 14%)               AR                                         Severe                       3
  c.1174A\>T/c.1229C\>T         1 (0. 14%)               AR                                         Severe                       1
  c.1225C\>T/c.1594A\>C         1 (0. 14%)               AR                                         Profound                     1
  c.1226G\>A/c.2168A\>G         1 (0. 14%)               AR                                         Profound                     1\. 5
  c.1229C\>T/c.2027T\>A         1 (0. 14%)               AR                                         Profound                     6 months
  c.1327G\>C/c.2168A\>G         1 (0. 14%)               AR                                         Profound                     1
  c.1334T\>G/c.1547_1548InsC    1 (0. 14%)               AR                                         Profound                     9 months
  c.1340delA/c.2027T\>A         1 (0. 14%)               AR                                         Profound                     2
  c.1343C\>T/c.1975G\>C         1 (0. 14%)               AR                                         Severe                       3
  c.1686_1687insA/c.2168A\>G    1 (0. 14%)               AR                                         Profound                     1
  c.1686_1687insA/c.2027T\>A    1 (0. 14%)               AR                                         Severe                       2\. 5
  c.1707+5G\>A/c.1975G\>C       1 (0. 14%)               AR                                         Profound                     3
  c.2027T\>A/c.2168A\>G         1 (0. 14%)               AR                                         Severe                       4
  Total                         140 (20. 1%)                                                                                     

\*AR: Autosomal recessive

10.1371/journal.pone.0165650.t006

###### Recessive Pathogenic Variants in *SLC26A4* in Patients with NSHL.

![](pone.0165650.t006){#pone.0165650.t006g}

  Base pair change   Effect or Amino acid change   TM[\*](#t006fn001){ref-type="table-fn"} domain   Number of subjects   Number of mutant alleles
  ------------------ ----------------------------- ------------------------------------------------ -------------------- --------------------------
  c.147C\>G          Ser49Arg                      NH2                                              2                    2
  c.227C\>T          Pro76Leu                      NH2                                              1                    1
  c.235C\>T          Arg79Ter                      NH2                                              1                    1
  c.249G\>A          Trp83 Ter                     NH2                                              1                    1
  c.269C\>T          Ser90Leu                      Exon 1                                           1                    1
  c.279T\>A          Ser93Arg                      Exon 1                                           2                    2
  c.281C\>T          Thr94Ile                      Exon 1                                           3                    3
  c.414delT          Frame-shift                   Exon 3                                           3                    5
  c.439A\>G          Met147Val                     Exon 3                                           1                    1
  c.563T\>C          Ile188Thr                     Exon 4                                           2                    2
  c.589G\>A          Gly197Arg                     Exon 4                                           1                    1
  c.754T\>C          Ser252Pro                     EC LOOP3                                         3                    3
  c.916_917insG      Frame-shift                   Exon 7                                           3                    3
  c.919-2A\>G        Splice site                   None                                             119                  169
  c.946G\>T          Gly316 Ter                    Exon 7                                           1                    1
  c.1079C\>T         Ala360Val                     Exon 8                                           1                    1
  c.1173C\>A         Cys391 Ter                    Exon 9                                           2                    2
  c.1174A\>T         Asn392Thr                     Exon 9                                           9                    9
  c.1225C\>T         Arg409Cys                     EC LOOP5                                         3                    3
  c.1226G\>A         Arg409His                     EC LOOP5                                         5                    5
  c.1229C\>T         Thr410Met                     EC LOOP5                                         5                    5
  c.1327G\>C         Glu443Gln                     IC LOOP5                                         1                    1
  c.1334T\>G         Leu445Trp                     IC LOOP5                                         1                    1
  c.1336C\>T         Gln446 Ter                    IC LOOP5                                         1                    1
  c.1340delA         Frame-shift                   IC LOOP5                                         2                    2
  c.1343C\>A         Ser448 Ter                    IC LOOP5                                         1                    1
  c.1343C\>T         Ser448Leu                     IC LOOP5                                         3                    3
  c.1371C\>A         Asn457Lys                     Exon 11                                          1                    1
  c.1489G\>A         Gly497Ser                     Exon12                                           1                    1
  c.1547_1548InsC    Frame-shift                   COOH                                             2                    2
  c.1586T\>G         Ser529Ala                     COOH                                             1                    1
  c.1594A\>C         Ser532Arg                     COOH                                             2                    2
  c.1673A\>T         Asn558Ile                     COOH                                             1                    1
  c.1686_1687insA    Frame-shift                   COOH                                             2                    2
  c.1707+5G\>A       Splice site                   COOH                                             6                    7
  c.1927G\>T         Glu643 Ter                    COOH                                             2                    2
  c.1975G\>C         Val659Leu                     COOH                                             14                   14
  c.1991C\>T         Ala664Val                     COOH                                             1                    1
  c.2027T\>A         Leu676Gln                     COOH                                             5                    5
  c.2167C\>G         His723Asp                     COOH                                             1                    1
  c.2168A\>G         His723Arg                     COOH                                             34                   35
  **Total**                                                                                         164                  304

\*TM: Transmembrane domains

*MT-RNR1* pathogenic variants {#sec010}
-----------------------------

*MT-RNR1* m.1555A \> G occurred in 6 patients (5 homoplasmons and 1 heteroplasmon). The mutant allele frequency of *MT-RNR1* was 0.86% (6/695). The percentage of homoplasmic *MT-RNR1* pathogenic variants was 0.72% (5/695) ([Table 7](#pone.0165650.t007){ref-type="table"}). Of the 5 cases with homoplasmic variants, 1 case had normal hearing, and then was found to be hard of hearing at 19 months, 2 weeks after the use of amikacin and 1 case showed characteristic down-sloping high-frequency hearing loss ([Fig 3](#pone.0165650.g003){ref-type="fig"}). *MT-RNR1* m.1494C \> T occurred in no subjects.

10.1371/journal.pone.0165650.t007

###### HL cases with *MT-RNR1* m.1555A\>G.

![](pone.0165650.t007){#pone.0165650.t007g}

  Number   Age (years)   Onset age(years)   Hearing loss                History of aa[\*](#t007fn001){ref-type="table-fn"}   m\. 1555A\>G
  -------- ------------- ------------------ --------------------------- ---------------------------------------------------- --------------
  1        5             19 months          All frequencies, profound   Amikacin                                             Homo
  2        3             1                  All frequencies, profound   Unclear                                              Homo
  3        22            Unclear            All frequencies, profound   Unclear                                              Homo
  4        3             2                  All frequencies, profound   Unclear                                              Homo
  5        3             2                  High frequencies. severe    Unclear                                              Homo
  6        7             3 days             All frequencies, profound   Unclear                                              Hetero

\*Aa: aminoglycoside antibiotics

![Patients with characteristic audiograms.\
(a) One case (female, 4 years old, onset at birth) with bi-allelic pathogenic variants in *GJB2* had a cochlear implant in the left ear and had profound hearing loss in the right ear. (b) One case (male, 3 years old, onset at 1 year old) with bi-allelic pathogenic variants in *SLC26A4* had a cochlear implant in the left ear and had severe hearing loss in the right ear. (c)One case (male, 3 years old, onset at 2 yrs) with homoplasmic *MT-RNR1* m.1555A \> G had a cochlear implant in the left ear and had severe hearing loss in the right ear with a down-sloping shaped audiogram, which is characteristic of aminoglycoside-induced HL.](pone.0165650.g003){#pone.0165650.g003}

Discussion {#sec011}
==========

*GJB2, SLC26A4*  {#sec012}
----------------

The *GJB2* gene, encoding gap junction protein Connexin 26(CX26), is the most frequent causative gene for NSHL. In this study, bi-allelic *GJB2* pathogenic variants accounted for 18.6% of HL among the 695 subjects in this study. This is comparable with the previously reported frequency of 17.9% in 2063 Chinese HL patients \[[@pone.0165650.ref009]\]. According to previous reports, pathogenic variants of c.35delG, c.167delT, and c.235delC are the 3 most frequent pathogenic variants in Caucasian, Ashkenazi Jewish, and Asian populations \[[@pone.0165650.ref010]--[@pone.0165650.ref014]\]. The frequency of c.235delC varies from 4% to 30.4% among different regions in China \[[@pone.0165650.ref009]\]. In this study, *GJB2* c.235delC was the most common pathogenic variant with a frequency of 13.0% (181/1390). Moreover, the panel in this study contained 18 unclassified *GJB2* variants with undetermined pathogenicity and 7 of these variants were detected in 50 of the 695 cases examined. The allele frequencies of c.109G \> A, c.95G \> A, c.283G \> A, c.571T \> C, c.23C \> T, c.408C \> A and c.416G \> A were 3.2%, 0.14%, 0.14%, 0.14%, 0.07%, 0.07%, and 0.07%, respectively. It's important to know that the pathogenic association between these variants and HL is uncertain and therefore the 3 subjects (one c.95G \> A and 2 c.109G \> A homozygotes) cannot assumed to be deaf or hard of hearing on the basis of having variants of unknown significance (VUS). The significance of this primary screening system was to collect subjects with VUSs; further studies must be done to investigate the possibility of a causative relationship between these variants and HL.

*SLC26A4* (OMIM\* 605646) plays a key role in maintaining the endo-cochlear potential and is the second most common causative gene for ARNSHL \[[@pone.0165650.ref003]--[@pone.0165650.ref005]\]. According to a previous study, *SLC26A4* bi-allelic pathogenic variants account for approximately 11% of Chinese Han probands with severe-to-profound HL and analysis of *SLC26A4* in 176 unrelated Chinese patients with ARNSHL demonstrated that 13.6% (24/176) of patients carried at least one mutant allele \[[@pone.0165650.ref015]\]. In this study, 23.6% patients were found to have genetic defects in *SLC26A4*, out of which, 20.1% carried bi-allelic pathogenic variants and 3.5% carried one mutant allele. The 5 most prevalent pathogenic variants, c.919-2A \> G, c.2168A \> G, c.1975G \> C, c.1174A \> T and c.1707+5G \> A, are detected in 77.0% of all mutant *SLC26A4* alleles.

Sensorineural hearing loss has been described as a monogenic disease, encompassing bi-allelic pathogenic variants in patients with ARNSHL. Genetic testing has previously been completed and a final molecular diagnosis has been made upon the identification of bi-allelic pathogenic variants within one gene. Inherited as a classic Mendelian trait, typical ARNSHL is caused by bi-allelic pathogenic variants in one gene, giving rise to a 25% risk of ARNSHL in the siblings of an HL subject. However, in the current study, 2 independent genes were involved in HL, indicating an increased risk prediction for siblings and further offspring of patients. In this study 3 patients carried bi-allelic *GJB2* variants and heterozygous *SLC26A4* variants and 2 patients carried bi-allelic *SLC26A4* variants and heterozygous *GJB2* variants. Simultaneous analysis of common HL genes yields more accurate genetic findings related to HL and has vital implications for improving genetic counseling and risk prediction. Furthermore, it's important to recognize that it cannot be assumed that having pathogenic variants in more than 1 gene is equivalent to di-genic inheritance. Without functional evidence, the conclusion for di-genic inheritance cannot be made.

*MT-RNR1*  {#sec013}
----------

The mitochondrial gene, *MT-RNR1* encodes 12S ribosomal RNA and is considered to be a chief cause for non-syndromic HL and aminoglycoside-induced HL \[[@pone.0165650.ref016]\]. Homoplasmic m.1555A \> G and m.1494C \> T, located at the highly conserved decoding site of the 12S ribosomal RNA gene, have been identified as a cause of maternally inherited non-syndromic HL. HL inherited through the mitochondria accounts for less than 1% of all HL, though the frequency of m.1555A \> G in Chinese non-syndromic HL patients can vary from 1.67%-15.5% \[[@pone.0165650.ref017]--[@pone.0165650.ref020]\]. In this study, 5 cases (0.72%,5/695) were found to carry homoplasmic m.1555A \> G, out of which, 1 had a history of aminoglycoside antibiotic usage and another had a recognizable audio-profile of aminoglycoside-induced HL. Thus, *MT-RNR1* m.1555A \> G is one possible reason for hearing loss in these 2 cases. However, it is important to recognize that even though *MT-RNR1* m.1555A \> G is not necessarily causative for HL, mitochondrial genes are transmitted maternally and therefore, identification of *MT-RNR1* m.1555A \> G and m.1494C \> T may have substantial implications for genetic counselling and offer an early warning for maternal members in the family pedigree.

SNPscan technique {#sec014}
-----------------

Single nucleotide polymorphisms (SNPs), the third generation of DNA genetic markers after Microsatellites, have been widely used in molecular genetics. In the current study, multiplex genotyping of 115 variants in 695 patients was successfully performed using an SNPscan technique developed by our team. It is a rapid and efficient molecular diagnostic strategy for identifying common genes related to deafness in Chinese populations and could be used clinically as a primary screening system, leading to advances in terms of power and cost efficiency.

This screening approach has been confirmed using Next Generation Sequencing and unpublished data from our lab showed that 18 pathogenic *GJB2* variants and 77 pathogenic *SLC26A4* variants in our panel detected 98% of all known *GJB2* and 96% of all known *SLC26A4* mutant alleles in our cohort. SNPscan analysis demonstrated that the cause of hearing loss in 61.3%(425/695) of subjects was unidentified; further analysis of all known genes related to deafness will be carried out using targeted genomic enrichment (TGE) and massively parallel sequencing (MPS).
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